Pieper Steven, the Chief Financial Officer of Xeris Biopharma Holdings, Inc., recently sold 5,000 shares of the company’s common stock. This transaction, reported on November 4, 2026, is significant as it highlights the ongoing management activities within the pharmaceutical sector.

The sale occurred on November 2, 2026, at a weighted average price of $10.2347 per share. The shares were sold as part of a Rule 10b5-1 trading plan that was adopted by Pieper on August 18, 2025. The plan allows for the systematic sale of shares to avoid any potential insider trading issues.

Following this transaction, Pieper Steven retains ownership of 1,346,053 shares of Xeris Biopharma. The filing indicates that the shares were sold in multiple transactions at prices ranging from $10.120 to $10.490.

Xeris Biopharma, based in Chicago, operates in the pharmaceutical preparations industry, focusing on innovative therapies. The company is known for its commitment to developing and commercializing products that address unmet medical needs.

This sale may reflect Pieper's personal financial strategy or a response to market conditions, but it underscores the active role of executives in managing their stock holdings. The pharmaceutical sector continues to face various challenges and opportunities, making such transactions noteworthy.

As of now, there are no indications of further actions or filings related to this transaction. The filing does not specify what happens next.